Metraipolis › archive › dc_2bd78822da3d
The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance — Europe PMC PMID:32421749
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/32421749
- DOI
- 10.1371/journal.pone.0233500
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-08T17:02:24.724Z
- SHA-256 of the archived text
5d1f6b8a9e5708506df39f24680550507ed624ed785a1ae370014acad2853a83- Stable URL of this page
https://metraipolis.com/documento/dc_2bd78822da3d
How to cite
The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance — Europe PMC PMID:32421749 — Europe PMC (en), https://europepmc.org/article/MED/32421749 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2bd78822da3d (Metraipolis archive dc_2bd78822da3d, sha256 5d1f6b8a9e5708506df39f24680550507ed624ed785a1ae370014acad2853a83)
BibTeX
@misc{dc2bd78822da3d,
title = {The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance — Europe PMC PMID:32421749},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/32421749},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2bd78822da3d; sha256 5d1f6b8a9e5708506df39f24680550507ed624ed785a1ae370014acad2853a83},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32421749. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Meta-analyses on impact of isoniazid-resistant tuberculosis informed the World Health Organization recommendation of a levofloxacin-strengthened rifampicin-based regimen. We estimated the effect of initial rifampicin resistance (Rr) and/or isoniazid resistance (Hr) on treatment failure or relapse. We also determined the frequency of missed initial and acquired Rr to estimate the impact of true Hr. Methods: Retrospective analysis of 7291 treatment episodes with known initial isoniazid and rifampicin status obtained from individual patient databases maintained by the Damien Foundation Bangladesh over 20 years. Drug susceptibility test results were confirmed by the programme's designated supra-national tuberculosis laboratory. To detect missed Rr among isolates routinely classified as Hr, rpoB gene sequencing was done randomly and on a sample selected for suspected missed Rr. Results: Initial Hr caused a large recurrence excess after the 8-month regimen for new cases (rifampicin for two months), but had little impact on rifampicin-throughout regimens: (6 months, new cases; 3.8%; OR 0.8, 95%CI:0.3,2.8; 8 months, retreatment cases: 7.3%, OR 1.8; 95%CI:1.3,2.6). Rr was missed in 7.6% of randomly selected "Hr" strains. Acquired Rr was frequent among recurrences on rifampicin-throughout regimens, particularly after the retreatment regimen (31.9%). It was higher in mono-Hr (29.3%; aOR 3.5, 95%CI:1.5,8.5) and poly-Hr (53.3%; aOR 10.2, 95%CI 4.4,23.7) than in susceptible tuberculosis, but virtually absent after the 8-month new case regimen. Comparing Bangladesh (low Rr prevalence) with a high Rr prevalence setting,true Hr corrected for missed Rr caused only 2-3 treatment failures per 1000 TB cases (of whom 27% were retreatments) in both. Conclusions: Our analysis reveals a non-negligible extent of misclassifying as isoniazid resistance of what is actually missed multidrug-resistant tuberculosis. Recommending for such cases a "strengthened" regimen containing a fluoroquinolone provokes a direct route to extensive resistance while offering little benefit against the minor role of true Hr tuberculosis in rifampicin-throughout first-line regimen. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-05-18). Identificativi: PMID 32421749 · PMCID PMC7233532 · DOI 10.1371/journal.pone.0233500. Descrittori MeSH principali: Drug Resistance. Pagina: https://europepmc.org/article/MED/32421749 — https://doi.org/10.1371/journal.pone.0233500. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-08T16:58:15.355Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.